{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 56,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a matrix-like layout to compare drug candidates by development stage and company, with a callout box for competitive advantages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/45",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.55,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "PRECLINICAL vs CLINICAL",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "577cbcfa-a141-4e7b-b742-4ead2cb1839b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.6,
        "y": 0.78
      },
      "kind": "disclaimer",
      "text": "1 Belvarafenib is also being evaluated... 2 NDA has been accepted... 3 Exarafenib in Ph 1b... ORR: overall response rate; SOC: standard of care; PoC: proof-of-concept",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d4c120e-9cd9-41bb-883a-5963c8460812",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.6,
        "y": 0.45
      },
      "kind": "list",
      "text": "PoC established in NRASm melanoma and RAS Q61X solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7288ec09-ed8e-4813-a299-193782608e48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.38,
        "x": 0.6,
        "y": 0.2
      },
      "kind": "list",
      "text": "Most advanced pan-RAF inhibitor; Dosed in 500+ patients; Potential to be first-to-market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b9ab6db-5417-4c1a-8f5c-da98fd34aa09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.6,
        "y": 0.65
      },
      "kind": "list",
      "text": "Strong complementarity with Erasca pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db976d87-8bff-49eb-94ed-617885765948",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Naporafenib: Potential first-in-class pan-RAF inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c354e44a-2077-4450-bb38-9d94389e598b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "1c5c963d-2814-493b-a704-1e84085d745a",
      "evidence": "list/bullet: Most advanced pan-RAF inhibitor; Dosed in 500+ patients; Potential to be first-to-market",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "ebe4b549-4b7e-4eef-9e98-3d59070a1299",
      "evidence": "Comparison of drug candidates across development stages",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}